4.6 Review

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature

期刊

ANTIBIOTICS-BASEL
卷 12, 期 8, 页码 -

出版社

MDPI
DOI: 10.3390/antibiotics12081328

关键词

ceftazidime-avibactam; osteomyelitis; arthritis; Pseudomonas aeruginosa

向作者/读者索取更多资源

BJIs caused by multidrug-resistant gram-negative bacteria are becoming a concern. Ceftazidime-avibactam has shown efficacy and safety in treating osteomyelitis and prosthetic joint infections, despite not being approved for these indications. This study presents three successful cases of resistant Pseudomonas aeruginosa osteomyelitis treated with ceftazidime-avibactam alone or in combination therapy.
Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and safety of ceftazidime-avibactam as a therapy for osteomyelitis and prosthetic joint infections. Here, we present three cases of difficult-to-treat resistant Pseudomonas aeruginosa osteomyelitis that were successfully treated with ceftazidime-avibactam alone or in combination therapy with fosfomycin and amikacin. Ceftazidime-avibactam was prescribed at a daily dose of 2.5 g every 8 h for 42 days in all cases. One potential drug-related adverse effect was observed, i.e., Clostridioides difficile infection, which occurred after fourteen days of treatment with ceftazidime-avibactam.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据